Looks to me like there are no intentions of ending OLE and EIND on CD12, and EUA is coming for COVID. Lack of information on CD16 supports that thesis, at least so far. IMHO, requiring further blinded trials withholding LL from placebo patients would be unethical given what is known from all actions and results with LL so far.